Lupin launches generic Mepron
Lupin announced the launch of its atovaquone oral suspension in 750 mg/5 mL dosage strengths.
The product is the generic equivalent of GlaxoSmithKline’s Mepron oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneumonia, or PCP, in adults and adolescents ages 13 years old and older who cannot tolerate trimethoprim-sulfamethoxazole, or TMP-SMX. It also is indicated for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years old and older who cannot tolerate TMP- SMX.
Atovaquone oral suspension had a market value of approximately $119 million, according to September 2018 IQVIA data.
The product is the generic equivalent of GlaxoSmithKline’s Mepron oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneumonia, or PCP, in adults and adolescents ages 13 years old and older who cannot tolerate trimethoprim-sulfamethoxazole, or TMP-SMX. It also is indicated for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years old and older who cannot tolerate TMP- SMX.
Atovaquone oral suspension had a market value of approximately $119 million, according to September 2018 IQVIA data.